Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Chromatogr A ; 1554: 117-122, 2018 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-29699870

RESUMEN

Chinoline alkaloids found in Cinchona bark still play an important role in medicine, for example as antimalarial and antiarrhythmic drugs. For the first time Supercritical Fluid Chromatography has been utilized for their separation. Six respective derivatives (dihydroquinidine, dihydroquinine, quinidine, quinine, cinchonine and cinchonidine) could be resolved in less than 7 min, and three of them quantified in crude plant extracts. The optimum stationary phase showed to be an Acquity UPC2 Torus DEA 1.7 µm column, the mobile phase comprised of CO2, acetonitrile, methanol and diethylamine. Method validation confirmed that the procedure is selective, accurate (recovery rates from 97.2% to 103.7%), precise (intra-day ≤2.2%, inter-day ≤3.0%) and linear (R2 ≥ 0.999); at 275 nm the observed detection limits were always below 2.5 µg/ml. In all of the samples analyzed cinchonine dominated (1.87%-2.30%), followed by quinine and cinchonidine. Their total content ranged from 4.75% to 5.20%. These values are in good agreement with published data, so that due to unmatched speed and environmental friendly character SFC is definitely an excellent alternative for the analysis of these important natural products.


Asunto(s)
Alcaloides/análisis , Cinchona/química , Alcaloides/química , Cromatografía con Fluido Supercrítico , Cinchona/metabolismo , Alcaloides de Cinchona/análisis , Límite de Detección , Corteza de la Planta/química , Corteza de la Planta/metabolismo , Extractos Vegetales/química , Quinidina/análogos & derivados , Quinidina/análisis , Quinina/análisis
3.
J Clin Pharmacol ; 55(3): 348-54, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25328082

RESUMEN

We investigated the effect of concurrent ingestion of Garcinia kola seed on the pharmacokinetics of quinine. In a randomized crossover study, 24 healthy Nigerian volunteers were assigned into 2 groups (A and B; n = 12 per group) on the basis of G. kola dose orally ingested. Each subject received 600 mg quinine sulfate before and after ingesting 12.5 g of G. kola once daily for 7 days (group A) or 12.5 g twice daily for 6 days and once on the seventh day (group B). Blood samples were collected and analyzed for plasma quinine and its metabolite (3-hydroxyquinine) using a validated high performance liquid chromatography method. Concurrent administration of quinine with G. kola reduced quinine tmax by 48% (group A), mean Cmax by 19% and 26% in groups A and B, respectively, and slight reduction in mean AUC0- ∞ of quinine in both groups. 3-hydroxyquinine Cmax also reduced by 29% and 32%; AUC0-∞ by 13% and 9%, respectively. The point estimates of the T/R ratio of the geometric means for all Cmax obtained and only the AUC0-∞ at a higher dose of G. kola were outside the 80%-125% bioequivalence range. In conclusion, an herb-drug interaction was noted with concurrent quinine and G. kola administration.


Asunto(s)
Suplementos Dietéticos , Garcinia kola , Quinina/farmacocinética , Semillas , Administración Oral , Adulto , Área Bajo la Curva , Biotransformación , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Suplementos Dietéticos/efectos adversos , Interacciones Farmacológicas , Femenino , Semivida , Voluntarios Sanos , Humanos , Masculino , Tasa de Depuración Metabólica , Nigeria , Quinidina/análogos & derivados , Quinidina/farmacocinética , Quinina/administración & dosificación , Quinina/efectos adversos , Quinina/sangre , Equivalencia Terapéutica , Adulto Joven
4.
Europace ; 16(4): 572-7, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24068450

RESUMEN

AIMS: To evaluate the long-term efficacy and safety of an electrophysiologically guided therapy, based on a strategy of treatment using hydroquinidine (HQ) among asymptomatic Brugada patients with inducible ventricular fibrillation (VF). METHODS AND RESULTS: In two French reference centres, consecutive asymptomatic type 1 Brugada patients with inducible VF were treated with HQ (600 mg/day, targeting a therapeutic range between 3 and 6 µmol/L) and enroled in a specific follow-up (mean 6.6 ± 3 years), including a second programmed ventricular stimulation (PVS) under HQ. An implantable cardioverter defibrillator (ICD) was eventually implanted in patients inducible under HQ, or during follow-up in case of HQ intolerance, as well as occurrence of arrhythmic events. From a total of 397 Brugada patients, 44 were enroled (47 ± 10 years, 95% male). Of these, 34 (77%) were no more inducible (Group PVS-), and were maintained under HQ alone during a mean follow-up of 6.2 ± 3 years. In this group, an ICD was eventually implanted in four patients (12%), with occurrence of appropriate ICD therapies in one. Among the 10 other patients (22%), who remained inducible and received ICD (Group PVS+), none of them received appropriate therapy during a mean follow-up of 7.7 ± 2 years. The overall annual rate of arrhythmic events was 1.04% (95% confidence interval 0.00-2.21), without any significant difference according to the result of PVS under HQ. One-third of patients experienced device-related complications. CONCLUSION: Our long-term follow-up results emphasize that the rate of arrhythmic events among asymptomatic Brugada patients with inducible VF remains low over time. Our results also suggest that residual inducibility under HQ is of limited value to predict events during follow-up.


Asunto(s)
Antiarrítmicos/uso terapéutico , Síndrome de Brugada/tratamiento farmacológico , Quinidina/análogos & derivados , Fibrilación Ventricular/prevención & control , Adulto , Antiarrítmicos/efectos adversos , Enfermedades Asintomáticas , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/fisiopatología , Desfibriladores Implantables , Cardioversión Eléctrica/instrumentación , Técnicas Electrofisiológicas Cardíacas , Femenino , Estudios de Seguimiento , Francia , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Quinidina/efectos adversos , Quinidina/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/fisiopatología
5.
Eur J Drug Metab Pharmacokinet ; 38(1): 63-7, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22945461

RESUMEN

Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity-induced and inhibited-is thought to be the driver of numerous poor or adverse therapeutic responses to up to 50 % of all commonly prescribed drugs. We carried out a genome-wide association study to identify common genetic variants associated with variation in induced CYP3A4 activity. A total of 310 twins were included in this study. Each participant had already completed a 14 days course of St John's Wort to induce CYP3A4, which was quantified through the metabolic ratio of exogenous 3-hydroxyquinine to quinine. We failed to detect any genome-wide significant associations (P < 1 × 10(-8)) with variation in induced CYP3A4 activity although several genomic regions were highlighted which may play minor roles. We report the first GWAS of variation in induced CYP3A4 activity and our preliminary results indicate a complex genetic architecture underpinning induced CYP3A4 enzyme activity.


Asunto(s)
Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Hígado/enzimología , Gemelos/genética , Anciano , Anciano de 80 o más Años , Biomarcadores/orina , Biotransformación , Citocromo P-450 CYP3A/biosíntesis , Inducción Enzimática , Femenino , Estudio de Asociación del Genoma Completo , Genotipo , Humanos , Hidroxilación , Hypericum , Hígado/efectos de los fármacos , Persona de Mediana Edad , Fenotipo , Preparaciones de Plantas/farmacología , Quinidina/análogos & derivados , Quinidina/orina , Quinina/orina , Especificidad por Sustrato
6.
J Am Coll Cardiol ; 60(2): 144-56, 2012 Jul 10.
Artículo en Inglés | MEDLINE | ID: mdl-22766342

RESUMEN

OBJECTIVES: The aim of this study was to describe a new familial cardiac phenotype and to elucidate the electrophysiological mechanism responsible for the disease. BACKGROUND: Mutations in several genes encoding ion channels, especially SCN5A, have emerged as the basis for a variety of inherited cardiac arrhythmias. METHODS: Three unrelated families comprising 21 individuals affected by multifocal ectopic Purkinje-related premature contractions (MEPPC) characterized by narrow junctional and rare sinus beats competing with numerous premature ventricular contractions with right and/or left bundle branch block patterns were identified. RESULTS: Dilated cardiomyopathy was identified in 6 patients, atrial arrhythmias were detected in 9 patients, and sudden death was reported in 5 individuals. Invasive electrophysiological studies demonstrated that premature ventricular complexes originated from the Purkinje tissue. Hydroquinidine treatment dramatically decreased the number of premature ventricular complexes. It normalized the contractile function in 2 patients. All the affected subjects carried the c.665G>A transition in the SCN5A gene. Patch-clamp studies of resulting p.Arg222Gln (R222Q) Nav1.5 revealed a net gain of function of the sodium channel, leading, in silico, to incomplete repolarization in Purkinje cells responsible for premature ventricular action potentials. In vitro and in silico studies recapitulated the normalization of the ventricular action potentials in the presence of quinidine. CONCLUSIONS: A new SCN5A-related cardiac syndrome, MEPPC, was identified. The SCN5A mutation leads to a gain of function of the sodium channel responsible for hyperexcitability of the fascicular-Purkinje system. The MEPPC syndrome is responsive to hydroquinidine.


Asunto(s)
Ramos Subendocárdicos/fisiopatología , Canales de Sodio/genética , Complejos Prematuros Ventriculares/genética , Adolescente , Adulto , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/genética , Cardiomiopatía Dilatada/genética , Niño , Análisis Mutacional de ADN , Muerte Súbita Cardíaca , Técnicas Electrofisiológicas Cardíacas , Femenino , Estudios de Asociación Genética , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Mutación , Contracción Miocárdica/efectos de los fármacos , Contracción Miocárdica/genética , Canal de Sodio Activado por Voltaje NAV1.5 , Técnicas de Placa-Clamp , Linaje , Fenotipo , Quinidina/análogos & derivados , Quinidina/uso terapéutico , Canales de Sodio/fisiología , Síndrome , Complejos Prematuros Ventriculares/tratamiento farmacológico , Complejos Prematuros Ventriculares/fisiopatología , Adulto Joven
7.
Pharmacogenet Genomics ; 21(10): 642-51, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21750469

RESUMEN

AIM: The cytochrome P450 3A4 (CYP3A4) enzyme is implicated in the metabolism of more than 50% of all prescribed medications and its activity - including induced or inhibited activity - is deemed to be a crucial determinant of interindividual variability in drug disposition, poor therapeutic efficacy, and adverse response to medication. METHODS: We used the classical twin model in conjunction with an induction experiment to uncover the relative contribution of genetic and environmental factors to interindividual variation in induced CYP3A4 activity. A total of 367 healthy twins participated in the study. Each volunteer was administered a potent inducer of CYP3A4 (St John's Wort) for 14 days and the activity of CYP3A4 was quantified through the metabolism of the exogenously administered probe drug quinine sulfate. RESULTS: Baseline and induced CYP3A4 activity were highly variable with a seven-fold and 11-fold difference among our population, respectively. Alcohol consumption, BMI, and smoking were significantly associated with induced CYP3A4 activity, collectively explaining 20% of the variation (P<1×10(-4)). The narrow-sense heritability of induced CYP3A4 activity was estimated at 66%, whereas the remainder of the variation was attributed to unique environmental factors. CONCLUSION: To our knowledge, this is the first genetic epidemiological study of induced CYP3A4 activity. Our results motivate further research to identify common and rarer genetic variants that underpin the heritable component of variation in induced CYP3A4 activity.


Asunto(s)
Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Hypericum , Extractos Vegetales/farmacología , Anciano , Anciano de 80 o más Años , Consumo de Bebidas Alcohólicas/genética , Consumo de Bebidas Alcohólicas/metabolismo , Biomarcadores Farmacológicos , Índice de Masa Corporal , Femenino , Humanos , Persona de Mediana Edad , Modelos Genéticos , Extractos Vegetales/administración & dosificación , Quinidina/análogos & derivados , Quinidina/orina , Quinina/farmacología , Quinina/orina , Fumar/genética , Fumar/metabolismo , Encuestas y Cuestionarios
8.
Mol Nutr Food Res ; 55(2): 185-97, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20827676

RESUMEN

SCOPE: Cytoprotective gene products, e.g. phase II - and antioxidant enzymes, are important in cellular redox homeostasis. A common feature of these genes is binding sites for transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2), named electrophile response elements (EpREs) within their promoters. METHODS AND RESULTS: To identify dietary bioactive compounds and foods with Nrf2/EpRE inducing properties in an intact organism, we utilized transgenic mice encoding luciferase under control of EpRE from the thioredoxin promoter. We found that 18 of 31 phytochemicals and 10 of 14 dietary plant extracts induced EpRE activity in liver HepG2 cells. Surprisingly, some dietary plant extracts showed profound inducing capability as compared to pure compounds indicating combinatorial effects of compounds found in whole foods. Furthermore, intraperitoneal injections of carnosol, curcumin and tert benzohydroquinine induced EpRE-dependent promoter activity in transgenic mice. In further experiments with curcumin, we found highly induced EpRE activity in intestine, liver, kidney and spleen. Finally, a combination extract made of coffee, thyme, broccoli, rosemary, turmeric and red onion fed orally, induced EpRE mediated luciferase in lung and adipose tissue. CONCLUSION: These results show that plant-based foods contain compounds that can be absorbed and induce the antioxidant defence in a living organism in an organ-specific manner.


Asunto(s)
Brassica/química , Café/química , Dieta , Factor 2 Relacionado con NF-E2/metabolismo , Extractos Vegetales/farmacología , Especias/análisis , Transcripción Genética/efectos de los fármacos , Abietanos/farmacología , Animales , Células Cultivadas , Curcumina/farmacología , Femenino , Copas de Floración/química , Genes Reporteros , Células Hep G2 , Humanos , Masculino , Ratones , Ratones Transgénicos , Factor 2 Relacionado con NF-E2/genética , Extractos Vegetales/química , Regiones Promotoras Genéticas/efectos de los fármacos , Quinidina/análogos & derivados , Quinidina/farmacología , ARN Mensajero/metabolismo
9.
Br J Haematol ; 149(4): 508-17, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20151979

RESUMEN

The present study found that the pentapeptide mimic C-61, targeting the substrate binding P-site of SYK tyrosine kinase acted as a potent inducer of apoptosis in chemotherapy-resistant SYK-expressing primary leukemic B-cell precursors taken directly from relapsed B-precursor leukaemia (BPL) patients (but not SYK-deficient infant pro-B leukaemia cells), exhibited favourable pharmacokinetics in mice and non-human primates, and eradicated in vivo clonogenic leukaemia cells in severe combined immunodeficient mouse xenograft models of chemotherapy-resistant human BPL at dose levels non-toxic to mice and non-human primates. These in vitro and in vivo findings provide proof of principle for effective treatment of chemotherapy-resistant BPL by targeting SYK-dependent anti-apoptotic blast cell survival machinery with a SYK P-Site inhibitor. Further development of C-61 may provide the foundation for therapeutic innovation against chemotherapy-resistant BPL.


Asunto(s)
Apoptosis/efectos de los fármacos , Péptidos y Proteínas de Señalización Intracelular/antagonistas & inhibidores , Ftalazinas/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Quinidina/análogos & derivados , Adolescente , Animales , Niño , Evaluación Preclínica de Medicamentos/métodos , Resistencia a Antineoplásicos , Femenino , Humanos , Macaca fascicularis , Masculino , Ratones , Ratones SCID , Ftalazinas/farmacología , Ftalazinas/toxicidad , Leucemia-Linfoma Linfoblástico de Células Precursoras/enzimología , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/toxicidad , Quinidina/farmacología , Quinidina/uso terapéutico , Quinidina/toxicidad , Análisis de Supervivencia , Quinasa Syk , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto , Adulto Joven
10.
Biomed Sci Instrum ; 38: 185-90, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12085599

RESUMEN

Recent research in our laboratories has been directed towards the development of ionomeric polymers and monomers for use in biomedical applications such as adhesives, drug delivery matrices and tissue scaffolds. The chemical Hydroquinone (HQ) aids as a stabilizer and represents a major component in the development of the ionomers. However, hydroquinone in high concentration has the potential to initiate carcinogenic effects on cells. The curing reactions are based on free radical chemistry that require a radical scavenger, ascorbic acid (Asc) to adjust working and setting times and shelf-life stability. The few studies published on HQ have suggested that high dosages of HQ may stimulate apoptosis as well as an increased cellular leakage, however the effect of HQ on the biocompatability is unknown. Therefore the objectives of this study were to measure the functional capacity, cell proliferation and structural integrity of Rhesus monkey kidney epithelial (RMK) cells exposed to ionomer formulations containing 4 different levels of HQ. A total of 90 tubes of RMK (40,000 cells per tube) cells were divided equally into five equal groups. Group I served as a control and group II-V were subjected to ionomers containing 0, 500, 1000, and 2000 ppm HQ. Cell numbers, morphology, cellular and supermatant MDA levels, and total protein analysis were performed. The results suggest: (I) All ionomer groups increased cellular proliferation except for the 2000 ppm HQ group, (II) MDA levels were increased in cells containing 2000 ppm HQ at 24 hours; and 0 ppm at 48 hours. It may be concluded that HQ concentrations over 1000 ppm may adversely affect biocompatability.


Asunto(s)
Transformación Celular Neoplásica/inducido químicamente , Riñón/citología , Quinidina/análogos & derivados , Quinidina/toxicidad , Animales , División Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Riñón/metabolismo , Macaca mulatta , Malondialdehído/metabolismo
12.
Eksp Klin Farmakol ; 56(3): 27-30, 1993.
Artículo en Ruso | MEDLINE | ID: mdl-8219985

RESUMEN

The antiarrhythmic activity and acute toxicity of polymeric formulations of quinidine, trimecaine, ethacizine, propranolol, verapamil which had been immobilized on a cellulose carrier (monocarboxylcellulose) and low molecular analogues were studied in various experimental animals (rats, mice, dogs). The polymeric formulations of trimecaine and verapamil were found to have a higher antiarrhythmic activity in different arrhythmia models than trimecaine and verapamil. The toxicity of all new compounds was no more than the values of conventional antiarrhythmic drugs.


Asunto(s)
Antiarrítmicos/uso terapéutico , Fenotiazinas/uso terapéutico , Propranolol/análogos & derivados , Quinidina/análogos & derivados , Trimecaína/análogos & derivados , Verapamilo/análogos & derivados , Animales , Antiarrítmicos/toxicidad , Arritmias Cardíacas/inducido químicamente , Arritmias Cardíacas/tratamiento farmacológico , Arritmias Cardíacas/mortalidad , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Ratones , Fenotiazinas/toxicidad , Polímeros , Propranolol/uso terapéutico , Propranolol/toxicidad , Quinidina/uso terapéutico , Quinidina/toxicidad , Ratas , Trimecaína/uso terapéutico , Trimecaína/toxicidad , Verapamilo/uso terapéutico , Verapamilo/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA